WiLD strengthens Nordic collaboration across Denmark, Finland, Norway and Sweden COPENHAGEN, Denmark and HELSINKI, Jan. 21, 2026 /PRNewswire/ — Women in Life ScienceWiLD strengthens Nordic collaboration across Denmark, Finland, Norway and Sweden COPENHAGEN, Denmark and HELSINKI, Jan. 21, 2026 /PRNewswire/ — Women in Life Science

Women in Life Science Denmark (WiLD) expands Nordic footprint with launch of WiLD Finland

WiLD strengthens Nordic collaboration across Denmark, Finland, Norway and Sweden

COPENHAGEN, Denmark and HELSINKI, Jan. 21, 2026 /PRNewswire/ — Women in Life Science Denmark (WiLD), the Nordic non-profit network dedicated to advancing women into senior leadership positions in life sciences, today announces the launch of WiLD Finland. WiLD’s expansion further strengthens its ambition to contribute to a more inclusive and competitive Nordic life sciences ecosystem by supporting and empowering women in life sciences.

Marking a significant milestone in WiLD’s continued Nordic expansion, the launch of WiLD Finland builds on the network’s established presence in Denmark and Norway, and its close collaboration with its Swedish sister organization, VILDA (Leading Women in Life Science, Sweden). Together, these organizations form a growing Nordic network focused on strengthening diversity, leadership and cross-border collaboration within the life sciences sector.

The official launch will take place on Wednesday, 21 January 2026, at an invitation-only leadership event hosted by Innovestor and The Embassy of Denmark in Helsinki, Finland. The launch event will bring together senior female leaders from across Finland’s life sciences ecosystem to introduce WiLD’s mission, peer groups, and mentoring activities, demonstrating how a Nordic network can support leadership development and systemic change.

H.E. Jakob Nymann-Lindegren, Danish Ambassador to Finland, said: “Strong Nordic cooperation is essential to building competitive and sustainable life sciences ecosystems. Initiatives such as WiLD play a significant role in strengthening cross-border collaboration while promoting greater diversity in leadership. I am pleased to host the launch of WiLD Finland at the Embassy and to support an initiative that brings together senior female leaders from across Denmark and Finland.”

The event will feature presentations by Dr. Lene Gerlach, Founder and Chair of WiLD Denmark, and Dr. Milla Koistinaho, Adjunct Professor in Neurobiology and Founding Partner at Innovestor Life Science, who will assume the role of Chair of WiLD Finland.

Dr. Milla Koistinaho, upcoming Chair of WiLD Finland, commented: “Finland has a strong and international competitive life sciences ecosystem, yet women remain underrepresented in senior leadership roles. WiLD Finland has been established to address this gap by creating a trusted, high-level network where women leaders can connect, share experiences, and support one another across sectors and borders. I am proud to introduce WiLD to Finland and bolster the strong Nordic collaboration already in place.”

Dr. Lene Gerlach, Founder and Chair of WiLD Denmark, remarked: “From the beginning, WiLD was founded with a Nordic ambition. Today, with active organizations in Denmark and Norway, close collaboration with VILDA in Sweden, and now the launch of WiLD Finland, we are building a strong, science-centric Nordic network for women in life sciences. By collaborating across countries, we can increase visibility of female role models, share best practices, and accelerate progress toward more diverse leadership in our sector.”

WiLD has established itself as a leading network across the Nordics through mentoring programs, peer-to-peer groups, networking events, and joint Nordic initiatives, including cross-border panels, surveys, and collaborations addressing shared leadership challenges across the region.

About Women in Life Science Denmark (WiLD)

Women in Life Science Denmark (WiLD) is a non-profit organization founded in Denmark, focused on increasing diversity in senior leadership positions across the life sciences for the benefit of society.

WiLD works to unfold the full talent potential of women in life sciences by increasing the visibility of female role models and by fostering professional knowledge sharing, mentoring, and strong networks. WiLD is part of a growing Nordic collaboration, with active organizations in Denmark, Norway and Finland, and close partnership with VILDA (Leading Women in Life Science, Sweden).

The organization is backed by the Novo Nordisk Foundation and Lundbeck Foundation. For more information, please visit www.womeninlifescience.dk

Cision View original content:https://www.prnewswire.com/news-releases/women-in-life-science-denmark-wild-expands-nordic-footprint-with-launch-of-wild-finland-302666546.html

SOURCE Women in Life Science Denmark (WiLD)

Market Opportunity
WilderWorld Logo
WilderWorld Price(WILD)
$0.0547
$0.0547$0.0547
-1.97%
USD
WilderWorld (WILD) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26